Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA: 600420)

Market Cap	14.00B
Revenue (ttm)	11.59B
Net Income (ttm)	1.07B
Shares Out	1.34B
EPS (ttm)	0.79
PE Ratio	13.14
Forward PE	10.88
Dividend	0.10 (0.96%)
Ex-Dividend Date	Jun 18, 2024

Volume	9,895,700
Open	10.80
Previous Close	10.79
Day's Range	10.43 - 10.85
52-Week Range	7.61 - 12.87
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Shanghai Shyndec Pharmaceutical

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, raw materials, and pharmaceutical preparations in China and internationally. The company’s pharmaceutical intermediate products primarily includes 7-ACA, 6-APA, penicillin industrial salt, etc.; API products for anti-infection applications comprising azithromycin, amoxicillin, potassium clavulanate, ceftriaxone sodium, etc., as well as urine source biochemical products and other characteristic raw materials; p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 11,608
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600420

Financial Performance

In 2023, 600420's revenue was 12.07 billion, a decrease of -6.86% compared to the previous year's 12.96 billion. Earnings were 691.88 million, an increase of 10.21%.